摘要
目的探讨晚期乳腺癌患者化疗前后血清血管内皮生长因子(VEGF)和基质金属蛋白酶-9(MMP-9)表达水平的变化与化疗疗效的关系。方法收集2012年12月1日至2014年12月1日江苏省肿瘤医院收治的65例晚期乳腺癌患者。全组患者均接受两药联合化疗方案,其中含铂方案39例,非含铂方案26例。在治疗前和化疗2个周期后,抽取患者的血清样本,检测VEGF和MMP-9的表达水平。比较化疗前后、不同疗效及不同化疗方案间血清VEGF和MMP-9的表达水平,并分析化疗后不同VEGF和MMP-9表达水平患者的中位疾病进展时间(TTP)。结果 65例乳腺癌患者化疗前VEGF的均值为596.5 pg/ml,MMP-9均值为686.5 ng/ml,显著高于化疗后的215.0 pg/ml和500.4 ng/ml,差异均有统计学意义(P<0.05)。56例临床获益患者化疗前后VEGF水平分别为678.1 pg/ml和232.0 pg/ml(P<0.05),MMP-9水平分别为679.3 ng/ml和450.6 ng/ml(P<0.05);9例疾病进展者化疗前后VEGF和MMP-9水平的差异无统计学意义(P>0.05)。39例接受含铂方案的患者,化疗前后MMP-9的均值分别为742.6 ng/ml和451.7 ng/ml(P<0.05),VEGF水平在化疗前后差异无统计学意义(P>0.05)。26例接受非含铂方案的患者,化疗前后VEGF和MMP-9水平的差异均无统计学意义(P>0.05)。化疗后30例MMP-9表达水平下降者的中位TTP为5.0个月,优于25例上升者的3.0个月(P<0.05);化疗后VEGF表达水平下降者与上升者的中位TTP比较,差异无统计学意义(P>0.05)。结论 VEGF和MMP-9表达水平降低可能是晚期乳腺癌患者化疗有效的参考指标。
Objective To study the relationship between the change of expression levels of vascular endothelial growth factors（ VEGF） and matrix metalloproteinase-9（ MMP-9） of advanced breast cancer patients before and after chemotherapy and the chemotherapy response. Methods Sixty-five advanced breast cancer patients in Jiangsu Cancer Hospital from December 1 2009 to December 12014 were enrolled in this study. All the patients were infused with two agents＇ chemotherapy,in which 39 were with platinum-based regimen and 26 received non-platinum-based regimen. Serum samples were collected from the 65 patients respectively before chemotherapy and after 2 cycles＇ chemotherapy to determine the expression levels of VEGF and MMP-9. The expression levels of VEGF and MMP-9 were compared before and after chemotherapy,between platinum-based regimen and non-platinum-based regimen as well as between different efficacies. Meanwhile the median time to progress（ TTP） of different expression of VEGF and MMP-9 were evaluated after chemotherapy. Results The mean value of serum VEGF and MMP-9 were 596. 5 pg / ml and 686. 5 ng / ml before chemotherapy,higher than 215. 0 pg / ml and 500. 4 ng / ml after chemotherapy（ P〈0. 05）. The expression level of VEGF of 56 patients with clinical benefit before and after chemotherapy was 678. 1 pg / ml and 232. 0 pg / ml（ P〈0. 05）,while the expression level of MMP-9 was 679. 3ng / ml and 450. 6 ng / ml（ P〈0. 05）. Those indexes in 9 patients with disease progression had no differences before and after chemotherapy（ P〉0. 05）. In 39 patients with platinum-based chemotherapy,the mean value of MMP-9 after chemotherapy were 451. 7 ng /ml,lower than 742. 6 ng / ml before chemotherapy（ P〈0. 05）. The median TTP of 30 patients with decreased level of MMP-9（ 5. 0months） was superior to the 25 patients with increased level of MMP-9（ 3. 0 months） with significant difference（ P〈0. 05）; whereas there was no significant difference between patients with the decreased
出处
《临床肿瘤学杂志》
CAS
2015年第12期1088-1092,共5页
Chinese Clinical Oncology
基金
江苏省肿瘤医院科研基金项目(ZM201204)
